Michel Rigaud, MD, PhD is a Professor of Biochemistry and Molecular Biology at the Medical Faculty of Limoges, France. His PhD was on organic chemistry at the University of Strasbourg and was centered on new graft silicons for glass capillary column chromatography (Chemical synthesis were published in Tetrahedron letters). This technology was applied in his lab to analysis of prostaglandins and leukotrienes and papers on this topic were published in Nature, Journal of Biological Chemistry, Journal of Immunology, Journal of Lipids, etc. Then, his research moved to oncology, particularly to neoangiogenesis and was published in Molecular Therapy. Now for three years he is working on CTCs and this year he created in a private laboratory (Astralab-Limoges) a platform of analyses on CTCs using molecular biology (RT-PCR multiplex on several markers) and start a clinical trial on breast cancer enrolling 400 patients with the aim to detect in the blood CTCs having stem cells characteristics. Rigaud was Head-chief of the clinical laboratory of the University hospital center during 10 years and also Director of a unit of CNRS. He has around 120 international published articles.
Biography Updated on 21 December 2008